Narrative review explores the effects of LI-RADS on diagnosis and treatment in patients with liver disease, suggesting improved outcomes.
Hepatocellular carcinoma (HCC) is a clinically significant primary liver malignancy that predominantly occurs in patients with cirrhosis and chronic liver disease. Early detection and accurate, non-invasive diagnosis are critical for improving survival outcomes, guiding therapeutic decision-making, and determining eligibility for liver transplantation. Imaging plays a central role in this process and frequently allows definitive diagnosis without the need for biopsy. The Liver Imaging Reporting and Data System (LI-RADS), developed by the American College of Radiology (ACR), was created to standardize liver imaging acquisition, interpretation, categorization, and reporting in populations at risk for HCC. Since its introduction, LI-RADS has evolved to encompass ultrasound surveillance, contrast-enhanced ultrasound, multiphase computed tomography, magnetic resonance imaging, and treatment response assessment algorithms, including nonradiation and radiation-based therapies. This narrative review provides a comprehensive overview of LI-RADS, encompassing its evolution and the latest developments in its diagnostic, surveillance, and treatment response algorithms.
No takes yet. Share an insight, caveat, or question.
Prajapati et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: